Acusphere Withdraws its European Marketing Authorization Application for Imagify
August 28 2014 - 11:25AM
Business Wire
Acusphere, Inc. (ACUSD.PK) announced today the strategic
decision to voluntarily withdraw its Marketing Authorization
Application (MAA) submitted to the European Medicines Agency’s
Committee for Medicinal Products for Human Use (CHMP) for Imagify™
(Perflubutane Polymer Microspheres for Injectable Suspension). The
Company intends to continue working with the U.S. Food and Drug
Administration (FDA) on the development of Imagify.
“The withdrawal of the MAA is a difficult but necessary decision
at this time. We are choosing to focus our resources on a pivotal
trial in the U.S. to strengthen Imagify’s total data package for
future partnering discussions and global regulatory submissions,”
said Mark Leuchtenberger, President and Chief Executive Officer of
Acusphere. “The withdrawal of the MAA in Europe does not affect the
status of Imagify’s Special Protocol Assessment with the FDA and we
remain committed to completing its clinical development.”
In May 2011, Acusphere reached an agreement with the FDA, under
a Special Protocol Assessment (SPA), on the design of a placebo
controlled trial to demonstrate that stress ultrasound with Imagify
has superior efficacy to stress ultrasound without Imagify.
About Acusphere, Inc.Acusphere, Inc. (ACUSD.PK) is a
specialty pharmaceutical company focused on the development and
regulatory approval of our lead product candidate, Imagify™
(Perflubutane Polymer Microspheres for Injectable Suspension).
Imagify is a cardiovascular drug for the detection of coronary
artery disease, the leading cause of death in the United States and
Europe. Imagify was created using proprietary technology that
enables Acusphere to control the porosity and size of nanoparticles
and microparticles, which were customized to control the delivery
of gas needed for ultrasound myocardial perfusion assessment. For
more information about Acusphere visit the Company’s website
(www.acusphere.com).
Media Contact:MacDougall Biomedical CommunicationsKari
Watson, 781-235-3060kwatson@macbiocom.comorBianca Nery,
781-235-3060bnery@macbiocom.com
Acusphere (CE) (USOTC:ACUS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Acusphere (CE) (USOTC:ACUS)
Historical Stock Chart
From Jan 2024 to Jan 2025
Real-Time news about Acusphere Inc New (CE) (OTCMarkets): 0 recent articles
More Acusphere, Inc. News Articles